Introduction
The assessment of ovarian reserve before ovarian stimulation is a major factor in the outcome of IVF. Currently, serum estradiol (E 2 ), FSH and inhibin B levels are examined and combined at the beginning of the menstrual cycle (day 3 or 4) to evaluate the functional status of the ovaries, providing information for appropriate ovarian stimulation treatment and prognosis for IVF outcome (Scott et al., 1989 (Scott et al., , 1990 Licciardi et al., 1995; Sharara et al. 1998) .
Several studies agree about the usefulness of the specific two-site enzyme-linked immunosorbent assay (ELISA) developed by Groome and O'Brien for inhibin B determination (Groome and O'Brien, 1993) . The cut-off value generally used for day 3 serum inhibin B is 45 pg/ml (Seifer et al., 1997) .
Non-isotopic or isotopic immunoassays for E 2 and FSH measurements are currently used in clinical laboratories and inconsistent hormone data are frequently reported, particularly for FSH, making the results difficult to interpret. These discrepancies are due to differences in methods (resulting from FSH polymorphism, antibody specificities and preparation of the standards) and result in decision limit values being different for different immunoassays.
The aim of this study was to compare FSH values obtained on day 3 of the menstrual cycle using six different immunoassays.
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Materials and methods
The study was a retrospective analytical investigation. We analysed serum from women donating oocytes in our IVF centre. These women underwent ovarian stimulation for oocyte retrieval. All were Ͻ35 years old, had regular menstrual cycles and were selected for the oocyte donation programme according to their day 3 hormonal status (E 2 , FSH and inhibin B concentrations). Blood samples were collected in Vacutainer ® (Becton-Dickinson, Plymouth, UK) glass systems without anticoagulant (serum) and were separated by centrifugation. All samples were placed in 300 µl aliquots in screw-capped Eppendorf ® tubes, frozen and stored at -70°C. A serum bank of 215 sera was thus constituted. As the volume of the samples obtained was limiting, the number of samples tested by each assay was between 77 and 215. The immunoassays tested included one isotopic method (FSH Coatria 125 I; Bio-Mérieux, Marcy l'Etoile, France) and five non-isotopic immunometric methods performed on automated multianalysers: ACS-180 (Bayer Diagnostics, Tarrytown, NY, USA), Advia-Centaur (Bayer Diagnostics), Vitros ECi (Ortho-Clinical Diagnostics Inc., Rochester, NY, USA), Architect i2000 (Abbott Laboratories, Abbott Park, IL, USA) and Elecsys 2010 (Roche Diagnostics, IND, USA). All are two-site immunoassays based on a one step method (except Architecht i2000, which is a two step method). The five non-isotopic assays are visualized by direct (Architect i2000, Advia-Centaur, ACS-180) or indirect (Vitros ECi) chemiluminescence or electrochemiluminescence (Elecsys 2010).
Before the clinical evaluation presented in this paper, for each method we analysed the precision (within and between runs) as described by the French National Committee for clinical laboratories (Vassault et al., 1999) . It was studied using pools of serum ranging over the calibration curves. Between-run precision was analysed per 30 days using two sets of reagents. All sera (n ϭ 215) were evaluated by ACS-180, a multi-analyser system routinely used in our Hormonology department. For the other methods tested, the number of samples analysed was between 77 for Elecsys 2010 (these samples were also evaluated by Coatria 125 I) and 133 for Vitros ECi (these samples included the 129 and 99 samples evaluated by Architect i200 and Advia-Centaur respectively). For each assay, mean and SD at day 3 were calculated. The paired Student's t-test, under Statview SE Software, was used for statistical analysis. A P-value Ͻ 0.05 was considered statistically significant.
Ethics
This study did not need approval by the French ethical committee. FSH measurements are required to evaluate the functional status of the ovaries before inclusion in an oocyte donation programme.
Results
All methods show coefficients of variation of Ͻ3% (intraassay) and Ͻ5% (inter-assay) for all analytic ranges (Ͻ5 to Ͼ50 mIU/ml; data not shown).
For day 3 FSH measurements, concentration ranges tested, mean results and SDs for each method are presented in Table I . For each assay, the concentration ranges analysed were similar: 3.2-17.4 mIU/ml for Elecsys 2010, 3.1-15.8 mIU/ml for Coatria 125 I, 3.4-18.4 mIU/ml for Advia-Centaur, 3.6-21.5 mIU/ml for Architect i2000, 2.8-19.8 mIU/ml for Vitros ECi and 3.4-20.8 mIU/ml for ACS-180. The means ranged between 6.5 (FSH Coatria 125 I) and 8.8 mIU/ml (Elecsys 2010) and the SD between 2.2 (FSH Coatria 125 I) and 3.3 mIU/ml (Architect i2000).
For ACS-180, two populations of samples (n ϭ 82 and 133) were tested. The difference between the two sets of sera was not statistically significant (P ϭ 0.11, non-paired Student's t-test) and they were consequently pooled for the study. The differences between all methods compared (on one hand, ACS-180, Coatria 125 I and Elecsys 2010 and on other hand, ACS-180, Advia-Centaur, Vitros ECi and Architect i2000) were statistically significant (P Ͻ 0.01, paired Student's t-test).
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Discussion
Differences observed between the different methods tested may be due to the overall structure of FSH, a glycoprotein assembled from two distinct α and β subunits and which presents heterogeneities in carbohydrate and peptide structures [different isoforms of FSH circulate (Stanton et al., 1992) ] affecting immunoreactivity. The specificity of the monoclonal and/or polyclonal antibodies used in the assay may be such that some FSH isoforms are quantified by some, but not all, immunoassays. Although, some manufacturers had included in their immunoassay procedures two monoclonal (anti-βFSH and anti-αFSH) antibodies (Architect i2000 and Coatria 125 I) or one monoclonal (anti-βFSH) and one polyclonal antibody (anti-αFSH; ACS-180, Advia-Centaur, Vitros ECi and Elecsys 2010), this approach was not sufficient to improve the immunoassay specificity.
The presence in the serum of various glycoproteins (LH, thyroid-stimulating hormone, HCG) structurally closely related to FSH (the same α subunit and homologies of the β subunits) could contribute to the observed discrepancies. However, it should be noted that all manufacturers have tested crossreactivities against these molecules and found no significant cross-reactivity. A central part of a measuring system is the standardization of assay. Although all manufacturers have tested their standard curve calibration ('secondary standard') against the same International Standard (NIBSC, 1998) , the matrix of the standard is required to be identical to the matrix of the specimen and this condition is met only rarely [note that a FSH human recombinant standard is in preparation (Rose and Gaines-Das, 1998) , which could diminish the influence of imperfect test standardization].
The last component which explains differences in assay measurements could result from the mathematical relationship permitting, on the system used, the conversion of the signal into the concentration of hormone. In our study, we did not find a clear difference in serum FSH between assays using monoclonal antibodies or monoclonal and polyclonal antibodies. We also did not find differences according to the signal measured (isotope, direct or indirect chemiluminescence). It is likely that a combination of all these factors, involved in the immunoassay procedure, contributes to the divergence of the results obtained (Büttner, 1991) . This lack of agreement between FSH immunoassays is also illustrated by the French National Quality Control which clearly shows two major and distinct populations of results (République Française, 1999) .
The present study, revealing statistically significant differences for day 3 FSH values according to the immunoassay used, raises issues for the interpretation of results from different clinical laboratories. FSH is widely used by physicians (in association with E 2 and inhibin B) as a criterion for inclusion in assisted reproductive technology programmes. The discrepancies observed indicate that it is advisable to refer patients to selected laboratories using analytical methods for which they have defined reference values and decision limits for this clinical situation. We hope that, as soon as possible, manufacturers will harmonize their routine immunoassay systems. These efforts toward standardization would be beneficial for both physicians and clinical laboratories and could avoid travelling and expense for the patients.
